Clinical Trial Update: Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating first-line sintilimab plus apatinib and S-1 with oxaliplatin (SOX) in AFP-producing gastric or gastroesophageal junction adeno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Stomach
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Anhui Provincial Cancer Hospital | Conditions: AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING